SCHEMBL10147459

SCHEMBL10147459

CCOC(=O)c1cc(-c2ccc(C)cc2C)no1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 2/20 0.44
MAPT P10636 6/20 0.42
LMNA P02545 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
KDM4E B2RXH2 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
TP53 P04637 2/20 0.41
HTT P42858 2/20 0.41
USP2 O75604 1/20 0.41
CA9 Q16790 1/20 0.41
GAA P10253 2/20 0.40
TDP1 Q9NUW8 3/20 0.39
ALDH1A1 P00352 3/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
THRB P10828 1/20 0.39
SLC26A6 Q9BXS9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299722 0.88 LMNA (0.48) MAPTLMNASMN1; SMN2HTTGAA
SCHEMBL6154640 0.85 KDM4E (0.42) MAPTKDM4EGAAALDH1A1L3MBTL1
SCHEMBL31124009 0.80 GAA (0.41) MAPTLMNANPSR1KDM4ESMN1; SMN2
SCHEMBL29775670 0.79 MAPT (0.49) ALPLMAPTNPSR1HTTRAB9A
SCHEMBL19814488 0.79 MAPT (0.49) ALPLMAPTNPSR1HTTRAB9A
SCHEMBL19766782 0.78 HSP90AA1 (0.38) MAPTLMNAKDM4ESMN1; SMN2TP53
SCHEMBL7669777 0.78 CYP1A2 (0.44) MAPTLMNAKDM4ESMN1; SMN2TP53
SCHEMBL2300298 0.77 LMNA (0.44) MAPTLMNASMN1; SMN2TP53HTT
SCHEMBL10147416 0.77 ALDH1A1 (0.53) MAPTLMNANPSR1KDM4ESMN1; SMN2
SCHEMBL892695 0.76 SMN1; SMN2 (0.58) MAPTKDM4ESMN1; SMN2TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993556-B2 Resorcinol derivatives as HSP90 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-03-31 US disclosed
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P ALPL 4155/4885MAPT 84/4885LMNA 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.